Communication FZJ-2022-02458

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png
P01.014 Spatial correlation of FET uptake and MRI contrast enhancement in newly diagnosed glioblastoma patients prior to treatment

 ;  ;  ;  ;  ;  ;  ;  ;  ;

2018

() [10.1093/neuonc/noy139.056]

This record in other databases:

Please use a persistent id in citations: doi:

Abstract: BackgroundA complete glioma resection is known to prolong survival. Contrast enhancement (CE) in MRI is usually the target for resection but the solid tumor mass may extend beyond the area of CE. It has been demonstrated that amino acid PET can detect tumor parts showing no CE in MRI. We systematically investigated the volumetric correlation of amino acid uptake with PET and CE in MRI in newly diagnosed and untreated glioblastoma patients.Material and MethodsPreoperatively, 26 patients were examined by O-(2-[18F]-fluoroethyl)-L-tyrosine (FET) PET and contrast-enhanced MRI. Enhancing tumor areas on MRI were manually segmented on each transverse section and the sum of the areas was multiplied by the slice thickness to obtain contrast-enhancing volumes. The calculation of FET PET tumor volumes was based on an auto-contouring process using a tumor-to-brain ratio of 1.6 or more. For volumetric comparison, the Dice and Jaccard spatial similarity coefficients (DSC; JSC) and the percentage of overlapping volumes (OV) were calculated. Postoperatively, a glioblastoma was confirmed neuropathologically in all patients.ResultsFET PET tumor volumes were significantly larger than contrast-enhancing volumes (26.7 ± 13.4 mL vs. 15.1 ± 11.5 mL; P=0.002). The spatial similarity between FET PET and CE was poor (mean DSC, 0.44 ± 0.18; mean JSC, 0.30 ± 0.14). Additionally, approximately one quarter of patients (n=7) showed a low spatial overlap (mean OV, 36 ± 18%).ConclusionThe present data suggest that the metabolic tumor volume as detected by FET PET is substantially underestimated by CE. Information derived from both imaging modalities should be integrated for the routine management of patients with newly diagnosed glioblastoma.

Classification:

Contributing Institute(s):
  1. Physik der Medizinischen Bildgebung (INM-4)
  2. Jara-Institut Quantum Information (INM-11)
  3. Jülich-Aachen Research Alliance - Translational Brain Medicine (JARA-BRAIN)
  4. Kognitive Neurowissenschaften (INM-3)
  5. Nuklearchemie (INM-5)
Research Program(s):
  1. 5253 - Neuroimaging (POF4-525) (POF4-525)

Database coverage:
Medline ; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; Essential Science Indicators ; IF >= 10 ; JCR ; NationallizenzNationallizenz ; PubMed Central ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection
Click to display QR Code for this record

The record appears in these collections:
Document types > Other Resources > Communication
Institute Collections > INM > INM-11
Institute Collections > INM > INM-3
Institute Collections > INM > INM-4
Institute Collections > INM > INM-5
Workflow collections > Public records
Publications database

 Record created 2022-06-21, last modified 2022-06-21



Rate this document:

Rate this document:
1
2
3
 
(Not yet reviewed)